NASDAQ · UFPT

UFP Technologies Inc.

$237.20 +$0.99 (+0.42%) 1D After hours

Key Metrics

$1.83B
Market cap
26.63×
P/E · TTM
$757.00M
Revenue · TTM
$68.62M
Net income
EPS · TTM $8.83
Dividend yield
Free cash flow
Beta · 1Y 0.96
EBITDA · TTM $100.77M
Gross margin 22.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 5
    The stock moved +10.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 5
  • Apr 29
    From its Feb 10 high, the share price fell 31%.

    Peak close $267.56 on Feb 10; trough close $185.45 on Apr 29. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31%
  • Feb 26
    The stock moved -10.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.83B
Enterprise value$1.95B
Shares outstanding7.7M
52-wk range$173.86 – $279.49
Avg volume · 20D81.3K
Net cash −$117.63M
Book value / share$56.44
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About UFP Technologies Inc.
IPO dateDec 23, 1993
Employees5349

UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E26.63
P/S2.41
P/FCF
EV/EBITDA19.30
EV/Sales2.57
Graham №$105.86

Profitability

Gross 22.8%
Operating 11.1%
Net 9.1%
FCF
ROE / ROIC 17.6% · 12.3%

Financial Health

Current ratio2.91
Quick ratio1.69
Debt / equity0.31
Debt / EBITDA 1.37
Net cash −$117.63M
Working capital$147.09M

Cash Flow · TTM

Operating CF $81.30M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

7.3
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$105.86 vs $237.20
Trades 2.2× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings